Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Oct. 17, 2014, 42 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $29.77 to $4,892,000.00.

Highlighted Stocks Traded by Insiders:

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan, who is SVP Software Development at Interactive Brokers Group, sold 1,800 shares at $23.39 on Oct. 17, 2014. Following this transaction, the SVP Software Development owned 701,417 shares meaning that the stake was reduced by 0.26% with the 1,800-share transaction.

The shares most recently traded at $24.63, up $1.24, or 5.05% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 14,400
  • 12-Week # shares sold: 49,500
  • 24-Week # shares sold: 78,300

The average volume for Interactive Brokers Group has been 399,500 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.4 billion and is part of the financial sector and financial services industry. Shares are up 1.03% year-to-date as of the close of trading on Friday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.65%. The company has a P/E ratio of 24.8. Currently, there are 2 analysts who rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Citigroup (C) - FREE Research Report

Aristeguieta Francisco, who is CEO, Latin America at Citigroup, sold 1,000 shares at $48.59 on Oct. 17, 2014. Following this transaction, the CEO, Latin America owned 44,071 shares meaning that the stake was reduced by 2.22% with the 1,000-share transaction.

The shares most recently traded at $50.02, up $1.43, or 2.86% since the insider transaction. Historical insider transactions for Citigroup go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 2,000

The average volume for Citigroup has been 17.0 million shares per day over the past 30 days. Citigroup has a market cap of $150.8 billion and is part of the financial sector and banking industry. Shares are down 3.91% year-to-date as of the close of trading on Friday.

Citigroup Inc., a diversified financial services holding company, provides various financial products and services to consumers, corporations, governments, and institutions. The stock currently has a dividend yield of 0.08%. The company has a P/E ratio of 17.7. Currently, there are 14 analysts who rate Citigroup a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on C - FREE

TheStreet Quant Ratings rates Citigroup as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Citigroup Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Acorda Therapeutics (ACOR) - FREE Research Report

Carrazana Enrique J., who is Chief Medical Officer at Acorda Therapeutics, sold 3,333 shares at $30.89 on Oct. 17, 2014. Following this transaction, the Chief Medical Officer owned 35,794 shares meaning that the stake was reduced by 8.52% with the 3,333-share transaction.

The shares most recently traded at $31.79, up $0.90, or 2.83% since the insider transaction. Historical insider transactions for Acorda Therapeutics go as follows:

  • 4-Week # shares sold: 9,700
  • 12-Week # shares sold: 9,700
  • 24-Week # shares sold: 9,700

The average volume for Acorda Therapeutics has been 679,300 shares per day over the past 30 days. Acorda Therapeutics has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 8.8% year-to-date as of the close of trading on Friday.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company has a P/E ratio of 71.0. Currently, there are 2 analysts who rate Acorda Therapeutics a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACOR - FREE

TheStreet Quant Ratings rates Acorda Therapeutics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Acorda Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null